Alto Neuroscience’s phase 2 depression trial has missed its primary efficacy endpoint, as patients on the drug candidate fared no better on a measure of alertness and mood than their peers on ...

Alto Ingredients, Inc. faces challenges typical of penny stocks, including a recent Nasdaq delisting warning due to its stock price falling below US$1.00 per share.

The $79 TCL Alto 8 Plus 2.1.2ch Soundbar Is a Big Upgrade From Your TV's Built-In Speakers Features Dolby Atmos surround sound and a discrete wireless subwoofer.

The Maruti Suzuki Alto, succeeding the iconic 800, took its name from the Suzuki Alto, a famed model in Japan. Rising during India's hatchback craze, it faced tough competition but prevailed through ...

Maruti Alto 800 2012-2016 was available at Rs 3.74 Lakh in New Delhi (ex-showroom). Read Alto 800 2012-2016 Reviews, view Mileage, Images, Specifications, Variants Details & get Alto 800 2012-2016 ...

Alto Ingredients, Inc. has a market cap of US$121.10 million and generates significant revenue from its Pekin Campus Production, Marketing and Distribution, and Western Production segments.

ALTO Updates the ART 01 Watch in Two Monochrome Editions: Arriving in Black and Titanium Gray.

Shares of Palo Alto Networks sank Friday morning despite the cybersecurity firm's results for the second quarter of fiscal 2025 coming in just above estimates.

Palo Alto Networks' "platformization" strategy in the earnings spotlight. Investors are looking for updates on Palo Alto’s NGS ARR and AI ARR. Geopolitical tensions, Fed uncertainty, and fast ...

Palo Alto reports first-quarter revenue of $2.14 billion, beating the consensus estimate of $2.12 billion. The cybersecurity company reports quarterly earnings of $1.56 per share, beating analyst ...

Palo Alto Networks said it will undertake a 2-for-1 forward split of the company's common stock. The cybersecurity company on Wednesday said its board of directors approved the stock split, which ...

This Phase 2 study consists of two sequential double-blind, placebo-controlled treatment periods and examines two doses of ALTO-203 and placebo given as monotherapy in patients with MDD.